The LIM homeobox 2 (Lhx2) transcription factor Lhx2 has a variety of functions, including neural induction, morphogenesis, and hematopoiesis. Here we show the involvement of Lhx2 in osteoclast differentiation. Lhx2 was strongly expressed in osteoclast precursor cells but its expression was significantly reduced during receptor activator of nuclear factor-jB ligand (RANKL)-mediated osteoclastogenesis. Overexpression of Lhx2 in bone marrow-derived monocyte/macrophage lineage cells (BMMs), which are osteoclast precursor cells, attenuated RANKL-induced osteoclast differentiation by inhibiting the induction of nuclear factor of activated T cells c1 (NFATc1). Interestingly, interaction of Lhx2 proteins with c-Fos attenuated the DNA-binding ability of c-Fos and thereby inhibited the transactivation of NFATc1. Furthermore, Lhx2 conditional knockout mice exhibited an osteoporotic bone phenotype, which was related with increased osteoclast formation in vivo. Taken together, our results suggest that Lhx2 acts as a negative regulator of osteoclast formation in vitro and in vivo. The anti-osteoclastogenic effect of Lhx2 may be useful for developing a therapeutic strategy for bone disease.
Bone homeostasis is maintained by a delicate balance between the activities of osteoblasts and those of osteoclasts. Excessive osteoclast activity relative to osteoblast activity leads to bone diseases such as osteoporosis. 1 Osteoblasts are mononuclear cells that are responsible for bone formation and osteoclast differentiation. Osteoblasts differentiate from mesenchymal progenitors under the control of various growth factors, in particular, the bone morphogenetic proteins (BMPs). 2 Osteoclasts are unique bone cells that can control the amount of bone tissue by resorbing mineralized bone matrix. Osteoclasts are characterized by tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells (MNCs) originate from hematopoietic precursors. Osteoclast formation requires two essential cytokines: macrophage colonystimulating factor (M-CSF) and receptor activator of nuclear factor kB ligand (RANKL). These membrane-bound proteins are produced by stromal cells and osteoblasts. Binding of M-CSF to its transmembrane receptor c-Fms induces receptor activation of nuclear kB (RANK) expression on osteoclast precursor cells by activating the Ets transcription factor PU.1 and thereby mediates the proliferation and survival of osteoclasts. 3 Binding of RANKL to its receptor RANK activates various transcription factors, including c-Fos, PU.1, and nuclear factor of activated T cells c1 (NFATc1), which have a critical role in osteoclastogenesis.
c-Fos, a member of the AP-1 family of transcription factors, is induced by RANKL in the early stage of osteoclast differentiation. c-Fos knockout mice exhibit an osteopetrotic bone phenotype because of defects in the commitment of the osteoclast lineage. 4, 5 Overexpression of c-Fos or NFATc1 in osteoclast precursor cells lacking c-Fos rescues the osteoclast differentiation defect. 6 RANKL activates c-Fos, NF-kB, and a sustained low-amplitude calcium oscillation, which results in the induction and activation of NFATc1. Subsequently, activated NFATc1 induces the expression of target genes, including TRAP, cathepsin K, and osteoclast-associated receptor (OSCAR), which are important for osteoclast differentiation or function. 4, 7, 8 NFATc1-deficient embryonic stem cells fail to differentiate into osteoclasts in response to RANKL. 4 In addition, osteoclast-specific conditional NFATc1-deficient mice, which were generated to overcome the embryonic lethality of NFATc1 knockout mice, develop osteopetrosis as a result of the defect in osteoclastogenesis. 9 Therefore, it has been well established that the RANKL/c-Fos/ NFATc1 signaling pathway is the critical converging pathway for osteoclast differentiation via induction of various osteoclast marker genes such as TRAP, cathepsin K, and OSCAR.
The LIM homeobox 2 transcription factor Lhx2 (also known as LH2 or LH2A) is a member of the LIM homeodomain family of proteins. Members of the LIM-homeodomain family are made of a homeodomain and two LIM domains that comprise two zinc-finger-like structures. The LIM domain can associate with various transcriptional cofactors and may modulate the biological functions of LIM-homeodomain proteins.
10 Lhx2 was originally identified in pituitary cells and in pre-B-cell lines. 11, 12 Lhx2 expression is essential in a wide variety of progenitor/stem cell populations. 13 Recent studies have shown that Lhx2 has important roles in eye development, liver differentiation, hair formation, and the complete development of olfactory sensory neurons. [14] [15] [16] In this study, we conducted a microarray analysis to find new regulatory molecules that may act as negative regulators during osteoclastogenesis. As a result of the microarray analysis, we found that Lhx2 expression is strongly downregulated during osteoclast differentiation. Overexpression of Lhx2 in bone marrow-derived monocyte/macrophage lineage cells (BMMs) inhibits RANKL-mediated osteoclastogenesis by inhibiting binding of c-Fos to the promoter of NFATc1, which suggests that Lhx2 acts as a negative regulatory molecule during RANKL-mediated osteoclastogenesis. Furthermore, our results from osteoclast-specific deletion of Lhx2 clearly established that Lhx2 can control bone mass by regulating osteoclast differentiation in vivo.
Results
Lhx2 expression is downregulated by RANKL during osteoclast differentiation. To examine the expression patterns of Lhx2, we performed real-time PCR in osteoclasts and osteoblasts. Osteoclast differentiation was induced by culturing BMMs in the presence of M-CSF and RANKL. Lhx2 expression was strongly downregulated by RANKL during osteoclast differentiation, whereas the expression of NFATc1 and TRAP, markers for osteoclasts, increased as the cells differentiated ( Figure 1a ). Because Lhx2 is downregulated by RANKL at the early stage of osteoclastogenesis, we determined which signaling pathways are essential for Lhx2 downregulation by using various inhibitors of early signaling pathways activated by RANKL. As shown in Supplementary  Figure 1 , treatment with SB203580 (p38 MAPK inhibitor), PD98059 (MEK inhibitor), and SP600125 (c-Jun N-terminal kinase (JNK) inhibitor) in BMMs did not affect Lhx2 expression downregulated by RANKL, whereas treatment with LY294002 (PI3K inhibitor) and TPCK (NF-kB inhibitor) significantly inhibited RANKL-induced Lhx2 downregulation. These results suggest that RANKL inhibits Lhx2 expression through AKT and NF-kB signaling pathways. To investigate the effect of pro-resorptive and anti-resorptive cytokines on Lhx2 expression, BMMs were treated with each cytokine overnight in the presence of M-CSF. Tumor necrosis factor (TNF)-a strongly reduced Lhx2 expression, whereas interferon (IFN)-a increased Lhx2 expression (Supplementary Figure 2) . Other cytokines (interleukin (IL)-6, IFN-b, IFN-g, and IL-4) showed effects in the opposite direction on Lhx2 expression.
Next, we examined the expression pattern of Lhx2 in primary osteoblasts cultured with osteogenic medium containing BMP2, ascorbic acid, and b-glycerophosphate. The expression of osteoblast marker genes including alkaline phosphatase (ALP) and bone sialoprotein was strongly increased during osteoblast differentiation, whereas Lhx2 expression was slightly increased (Figure 1b) .
Overexpression of Lhx2 in osteoclast precursor cells inhibits RANKL-induced osteoclast formation. To investigate the role of Lhx2 in osteoclasts and osteoblasts, we overexpressed Lhx2 in BMMs and primary calvarial cells by using retrovirus. Transduced BMMs were cultured with M-CSF alone or M-CSF and RANKL and stained for TRAP. RANKL treatment of control vector-infected BMMs increased the number of TRAP( þ ) MNCs in a dose-dependent manner, whereas overexpression of Lhx2 in BMMs significantly inhibited the formation of TRAP( þ ) MNCs mediated by M-CSF and RANKL (Figures 2a and b) . Next, to investigate the role of Lhx2 in osteoblasts, we examined the effect of Lhx2 on ALP activity and nodule formation in primary calvarial cells. Compared with osteoclasts, overexpression of Lhx2 had little effect on BMP-induced ALP activity and nodule formation (Figures 2c and d) . Taken together, these data suggested that Lhx2 has a critical role in RANKL-mediated osteoclast differentiation. Figure 3) . In addition, when BMMs were cocultured with transduced primary osteoblasts in the presence of 1,25(OH) 2 D 3 alone or 1,25(OH) 2 D 3 and PGE 2 , the number of TRAP( þ ) MNCs was not changed by overexpression of Lhx2 in osteoblasts compared with the control (Supplementary Figures 4a and b) . Therefore, these results suggested that Lhx2 may modulate osteoclast differentiation via direct action on osteoclast precursors rather than via indirect action on osteoblasts.
Overexpression of Lhx2 attenuates NFATc1 expression. Given our observation that overexpression of Lhx2 inhibits RANKL-mediated osteoclast differentiation, we examined the effect of Lhx2 on RANKL-induced early signaling pathways such as NF-kB, JNK, p38, and extracellular signal-regulated kinase (ERK). Among these signaling pathways, RANKLinduced activation of JNK, but not other signaling cascades, was slightly attenuated by overexpression of Lhx2 in BMMs (Supplementary Figure 5) . Next, we investigated whether overexpression of Lhx2 could affect the expression of genes known to have a role in osteoclastogenesis. The expression of c-Fos at an early stage of osteoclastogenesis was not affected by overexpression of Lhx2 (Figures 3a and b) . However, compared with control, exogenous overexpression of Lhx2 attenuated the expression of NFATc1 as well as of marker genes such as TRAP and OSCAR during RANKLmediated osteoclastogenesis (Figures 3c and d) . Therefore, these results further confirmed that Lhx2 has a role in osteoclast differentiation by modulating signals downstream from RANKL.
Lhx2 attenuates the binding ability of c-Fos. Because overexpression of Lhx2 attenuated RANKL-induced NFATc1 expression, we investigated whether Lhx2 could regulate the ability of c-Fos, an upstream transcription factor of NFATc1, to induce NFATc1 gene expression. We used a reporter assay involving transient transfection into highly transfectable 293 human embryonic kidney cells (293T). When a reporter plasmid containing a 6.2-kb NFATc1 promoter region was cotransfected with c-Fos, relative luciferase activity was increased ( Figure 4a ). However, Lhx2 decreased the induction of luciferase activity by c-Fos in a dose-dependent manner.
To investigate the inhibitory mechanism of Lhx2 on c-Fos transcription activity, we used a glutathione S-transferase (GST) pull-down assay to determine the interaction between Lhx2 and c-Fos. GST alone or GST-Lhx2 fusion proteins immobilized on glutathione-Sepharose beads were incubated with cell lysates containing Flag-tagged c-Fos. As shown in Figure 4b , c-Fos was retained by GST-Lhx2, but not by GST alone. Next, we also investigated whether endogenous Lhx2 and c-Fos interact with each other in preosteoclasts. We confirmed a direct interaction between Lhx2 and c-Fos in preosteoclasts (Supplementary Figure 6) .
To determine whether Lhx2 proteins can modulate the binding of c-Fos to AP1-binding sites in the NFATc1 promoter region, we carried out an electrophoretic mobility shift assay (EMSA) in the presence of GST-Lhx2 fusion proteins. We observed a shift in the c-Fos-specific band resulting from the reaction mixture containing c-Fos translated in vitro with the probe containing the AP1-binding site. The specificity of this binding was confirmed by competition studies using cold wild-type and mutant competitor probes. When the purified GST-Lhx2 fusion proteins were added to the reaction mixture, we observed a significant decrease in c-Fos binding to labeled probe caused by GST-Lhx2 proteins, but not by GST alone (Figure 4c In addition, the silencing of Lhx2 in BMMs resulted in a significant increase in the induction of NFATc1 and marker genes such as TRAP and OSCAR in response to RANKL stimulation (Figure 5c ). Taken together, these results suggested that Lhx2 has an important role in RANKL-induced osteoclastogenesis.
Deletion of Lhx2 results in reduced bone mass in vivo. To examine the effect of Lhx2 on the bone phenotype and osteoclast formation in vivo, we generated Mx1-cre-mediated Lhx2 conditional knockout mice. Control (Lhx2 fl/fl ) and Lhx2 conditional knockout mice (Lhx2 fl/fl ; Mx1-Cre) were intraperitoneally injected with polyinosinicpolycytidylic acid (polyI:C) every other day for a total of three doses at 2 weeks of age to induce Mx1-cre expression. We confirmed the reduction of Lhx2 expression in long bone, osteoclast precursor cells, and osteoclasts of Lhx2 conditional knockout mice by using quantitative real-time PCR analysis (Figures 6c-e) . Consistent with results from experiments using siRNAs, in BMMs derived from Lhx2 conditional knockout mice, RANKL-induced osteoclast differentiation was significantly increased (Figures 6a and b) . Also, Mx1-cre-mediated reduction of Lhx2 in BMMs resulted in a significant increase in the induction of NFATc1, TRAP, and OSCAR mediated by RANKL (Figure 6e) .
Next, we analyzed the bone phenotype to examine the effect of Lhx2 deletion on osteoclast formation in vivo. Micro-computed tomography (mCT) analysis showed a (Figure 7a ). The percentage of bone volume to total tissue volume and the trabecular number of Lhx2 conditional knockout mice were lower than those of control mice, which suggests that Lhx2 conditional knockout mice exhibit an osteoporotic phenotype (Figure 7b ). To further confirm the phenotype of Lhx2 conditional knockout mice, we performed histomorphometric analysis in the proximal tibiae. As shown in Figures 7c-e, both osteoclast number and osteoclast surface area were significantly increased in Lhx2 conditional knockout mice (Figures 7c and e) , whereas osteoblast number was not significantly different between control mice and Lhx2 conditional knockout mice (Figure 7e) . Therefore, these results indicated that reduction of Lhx2 resulted in the phenotype of decreased bone mass with increased osteoclast formation in vivo.
Discussion
Homeobox genes have a major role in development. 19 LIM-homeodomain proteins are encoded by a subfamily of homeobox-containing genes. The LIM domain recognizes a variety of transcriptional cofactors through protein-protein interaction. Thus, combinational interaction of LIM domains with other transcriptional regulators in a homometric or heterometric manner enables LIM-homeodomain proteins to participate in a wide range of developmental events by means of tissue-specific transcriptional regulation. 10, 19 Here, for the first time, we suggest a novel role of Lhx2, a member of the LIM-homeodomain family of proteins, as a negative regulator of RANKL-induced osteoclast differentiation. We found that RANKL strongly downregulates Lhx2 expression during osteoclast differentiation. Overexpression of Lhx2 in BMMs attenuates RANKL-induced osteoclast differentiation by downregulation of NFATc1, which is a key modulator for osteoclast differentiation. In addition, we observed that Lhx2 interacts directly with c-Fos and inhibits its transcriptional activity by blocking recruitment of c-Fos to AP1-binding sites of the NFATc1 promoter. Thus, inhibition of Lhx2 expression by RANKL at the early stage of osteoclast differentiation likely enables c-Fos to bind to the NFATc1 promoter region. Subsequently, NFATc1 leads to the robust induction of TRAP and OSCAR, which are important for Previous studies have suggested that Lhx2 can act as a transcriptional activator or repressor by means of several mechanisms depending on the target genes. Lhx2 can activate transcription of the thyroid-stimulating hormone b subunit gene through direct binding to the Lhx2-binding region of the promoter. 20 Hou et al. demonstrated that Lhx2 binds to enhancers rather than the promoter of PAX6 to induce neural differentiation from human embryonic stem cells. 21 Also, the LIM domain of Lhx2 functions as a coactivator through interaction with MRG1, leading to recruitment of p300/CBP to stimulate glycoprotein hormone a-subunit gene expression. 22 On the other hand, Lhx2 negatively regulates the PRL promoter in pituitary cell lines by an as yet unknown mechanism. 23 In the present study, we elucidated the mechanism of action of Lhx2 as a negative regulator during osteoclastogenesis. The expression patterns of c-Fos, NFATc1, and Lhx2 during RANKL-induced osteoclastogenesis suggest that Lhx2 may repress c-Fos. During osteoclastogenesis, RANKL strongly induces the expression of c-Fos and NFATc1 and simultaneously downregulates the expression of Lhx2. In addition, overexpression of Lhx2 in BMMs attenuates transcription of the target gene of c-Fos. In our ChIP assays and EMSA assay, Lhx2 did not appear to directly bind to the NFATc1 promoter but appeared to inhibit binding of c-Fos to the promoter region of NFATc1. In addition, given our results that Lhx2 proteins interact with c-Fos in vitro, these findings suggest a model in which Lhx2 represses transcription of the target gene of c-Fos through interaction with this important transcription factor in osteoclasts.
Because Lhx2 knockout mice die a few days before birth owing to severe anemia, we generated Mx1-cre-mediated Lhx2 conditional knockout mice to confirm the effect of Lhx2 on the bone phenotype in vivo.
16 Mx1-cre-mediated deletion of Lhx2 in mice resulted in an osteoporotic bone phenotype owing to increased osteoclast differentiation. Our Lhx2 conditional knockout mice exhibited no significant effect on osteoblast differentiation. These results may be caused from use of the inducible Mx1-cre and polyI:C system to specifically delete Lhx2 in IFN-responsive cells including monocyte and macrophage cells. However, our Lhx2 conditional knockout mice suggest that Lhx2 regulates bone remodeling in vivo by inhibiting osteoclast formation. Our results in the conditional knockout mice also suggest that the expression levels of Lhx2 in osteoclasts have no effect on osteoblast differentiation regulated by osteoclasts.
It is known that Lhx2 has an important role in regulating extracellular signaling pathways including the WNT and BMP pathways during neural development. Lhx2 activates antagonists of WNT and BMP protein in certain areas to inhibit these signaling pathways in the developing forebrain. 21, 24 Because WNT and BMP signaling are involved in osteoblast differentiation and bone formation, we examined whether Lhx2 directly affects osteoblast differentiation and function. 25 Overexpression of Lhx2 in osteoblasts showed a marginal effect on BMP2-mediated osteoblast differentiation and nodule formation (Figures 2c and d) . Therefore, our and previous results collectively suggest that Lhx2 differentially regulates downstream signaling in a cell-type-specific manner. BMPs can function in osteoclasts as well as in osteoblasts. BMPs act synergistically with RANKL for induction of osteoclast formation from osteoclast precursors and directly stimulate mature osteoclast function mediated by downstream molecules expressed in osteoclasts. 26 Although Lhx2 may have no effect on downstream molecules of BMP2 expressed in osteoblasts, we cannot be sure whether Lhx2 regulates the BMP signaling pathway during RANKL-induced osteoclastogenesis. Thus, further study will be required to elucidate the role of Lhx2 in osteoclast differentiation and function mediated by the BMP signaling pathway.
In our and previous results, it was shown that RANKL inhibits the expression of the MafB, Ids, and IRF8 genes, which are negative regulators of osteoclastogenesis. [27] [28] [29] Here, we add Lhx2 to this list of negative regulators. Taken together, our results demonstrate that RANKL not only activates positive regulators such as c-Fos and NFATc1 but also represses negative regulators such as MafB, Ids, and Lhx2 to maximize the ability of the positive regulators for sufficient osteoclast formation.
TNF-a as well as RANKL represses the expression of Lhx2 (Supplementary Figure 2) . TNF-a, a proinflammatory cytokine, may be responsible for osteoclast differentiation and activation in inflammatory bone diseases such as rheumatoid arthritis.
30,31 Interestingly, we confirmed that overexpression of Lhx2 in BMMs significantly inhibited the formation of TRAP( þ ) MNCs mediated by M-CSF and TNF-a (Supplementary Figure 7) . Therefore, further study of the precise mechanism of Lhx2 in osteoclasts may provide a new therapeutic strategy for bone diseases including osteoporosis and rheumatoid arthritis.
Materials and Methods
Reagents. Antibodies specific for Flag and actin were purchased from Sigma-Aldrich (St. Louis, MO, USA); c-Fos and NFATc1 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); and GST, phospho-p38, p38, phospho-JNK, JNK, phospho-Erk, Erk, and IkB were from Cell Signaling Technology (Beverly, MA, USA). A polyclonal antibody for OSCAR was prepared as previously described. 7 TNF-a, IL-1, IL-6, and IL-4 were purchased from R&D systems (Minneapolis, MN, USA).
Osteoclast differentiation. Mouse bone marrow cells were isolated from tibiae and femurs of 6-week-old mice by flushing the bone marrow with a-minimal essential medium (a-MEM). Bone marrow cells were cultured in a-MEM containing 10% fetal bovine serum with M-CSF (30 ng/ml) for 3 days. Adherent cells were used as osteoclast precursors (BMMs) and BMMs were further cultured with M-CSF (30 ng/ml) and RANKL (100 ng/ml) for 3 days. Primary osteoblasts and BMMs were cocultured for 5 days in the presence of 1,25(OH) 2 D 3 (1 Â 10 À 8 M) and PGE 2 (1 Â 10 À 6 M). Cultured cells were fixed and stained with TRAP solution (Sigma-Aldrich) according to the manufacturer's instructions. TRAP-positive cells with more than three nuclei were counted as TRAP-positive MNCs. Cells were observed by using a Leica DMIRB microscope equipped with an N Plan 10 Â 0.25 numerical aperture objective lens (Leica, Wetzlar, Germany). Images were captured by using a ProgRes Capture Pro (Jenoptik, Jena, Germany).
Osteoblast differentiation. Primary osteoblasts were prepared from calvariae of newborn mice by enzymatic digestion in a-MEM with 0.1% collagenase (Invitrogen, Carlsbad, CA, USA) and 0.2% dispase (Roche Applied Sciences, Indianapolis, IN, USA). To induce osteoblast differentiation, cells were cultured in a-MEM containing 10% fetal bovine serum with BMP2 (50 ng/ml), b-glycerophosphate (100 mM), and ascorbic acid (50 mg/ml). For the ALP activity assay, cells were lysed at day 4 of culture and cell lysates were incubated with the enzyme's nonspecific substrate, p-nitrophenyl phosphate (Sigma-Aldrich). ALP activity was measured spectrophotometrically at 405 nm. For alizarin red staining, cells were fixed at day 9 of culture and stained with 40 mM pH 4.2 alizarin red solution.
Retroviral infection. To prepare retroviral supernatants, retroviral vectors were transfected into the packaging cell line Plat E by using FuGENE 6 Luciferase assay. 293T cells were plated on 24-well plates at a density of 2 Â 10 4 cells per well 1 day before transfection. Reporter plasmid and various expression vectors were cotransfected into the cells by using FuGENE 6 according to the manufacturer's instruction. After 2 days of transfection, the cells were lysed in reporter lysis buffer (Promega, Madison, WI, USA) and then luciferase activity was measured with a dual-luciferase reporter assay system (Promega) according to the manufacturer's instructions.
GST pull-down assay. GST or GST-Lhx2 proteins were expressed in Escherichia coli BL21 (DE) and purified with glutathione-Sepharose 4B beads (Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer's instructions. 293T cells were transfected with Flag-c-Fos and lysed in 0.5% Nonidet P-40 lysis buffer. Cell lysates were incubated with either GST or GSTLhx2 proteins for 3 h and further incubated with glutathione-Sepharose 4B beads. Precipitated samples were subjected to SDS-PAGE and western blotting.
EMSA. c-Fos proteins were synthesized by using a TNT-coupled rabbit reticulocyte lysate system (Promega). An amount of 4 mg of TNT cell lysate, 2 mg of poly (dI-dC), and 50 000 cpm-labeled probes were incubated in reaction buffer (10 mM HEPE, pH 8.0, 0.5 mM dithiothreitol, 50 mM KCL, 5 mM MgCl 2 , 1 mM EDTA, protease inhibitors, and 5% glycerol) at 25 1C for 30 min. Samples were resolved on a 5% native polyacrylamide gel in 0.25 TBE buffer. Wild-and mutanttype sequences of AP1-binding sites were as follows: wild-type AP1-binding site, 5
0 -AGCCCGGCCCTGCGTCAGAGTGAGAC-3 0 and 5 0 -GTCTCACTCTGACGCAG GGCCGGGCT-3 0 , mutant-type AP1-binding site, 5 0 -AGCCCGGCCCAACGTAG GAGTGAGAC-3 0 and 5 0 -GTCTCACTCCTACGTTGGGCCGGGCT-3 0 .
ChIP assay. A ChIP assay was performed with the ChIP kit (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. Briefly, BMMs were transduced with pMX-IRES-EGFP (control) or Lhx2 retrovirus and were cultured with M-CSF and RANKL for 1 day. Cultured cells were cross-linked with 1% formaldehyde for 10 min at 37 1C and were lysed in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1, 0.01% protease inhibitor mixture). Cells were sonicated to shear the DNA into small fragments of an average length between 200 and 1000 base pairs. Diluted supernatants were immunoprecipitated with antic-Fos or control IgG (SantaCruz Biotechnology), washed, and then eluted in fresh elution buffer (0.1 M NaHCO 3 and 1% SDS). After cross-link reversal and Proteinase K treatment, DNA samples were recovered by phenol/chloroform extraction and ethanol precipitation. The purified DNA samples were subjected to PCR amplification with primers specific for the promoter regions of NFATc1-containing c-Fos-binding sites. The primer sequences are as follows; NFATc1, 5 0 -CCGGGACGCCCATGCAATCTGTTAGTAATT-3, and 5 0 -GCGGGTGCCCTG AGAAAGCTACTCTCCCTT-3 0 .
siRNA transfection. Control siRNAs and Lhx2 siRNAs were purchased from Dharmacon (Lafayette, CO, USA). The siRNAs were transfected into BMMs by using lipofectamine 2000 (Invitrogen).
Lhx2 conditional knockout mice. Lhx2 fl/fl mice were previously generated and have been described. 32 To generate Lhx2 conditional knockout mice ( ;Mx1-Cre) at 2 weeks of age were intraperitoneally injected with 200 mg of polyI:C every other day for a total of three doses to activate Mx1-Cre.
lCT and histomorphometric analyses. We analyzed the femurs of 10-week-old female mice by using mCT (Skyscan 1172, Skyscan, Kontich, Belgium). The X-ray source was set at 50 kV and 200 A with a pixel size of 17.09 mm. Exposure time was 1.2 s. Four-hundred and fifty projections were acquired over an angular range of 1801 (angular step of 0.41). The image slices were reconstructed by using 3D CT analyzer software (CTAN, Skyscan). Trabecular morphometry was characterized by measuring the bone volume fraction and trabecular thickness. For static histomorphometry, the tibia from each mouse was removed and fixed in 4% paraformaldehyde in PBS at 4 1C, decalcified in 12% EDTA for 4 weeks, and embedded in paraffin. Tissue sections of 5-mm thickness were subjected to TRAP staining or hematoxylin/eosin staining according to standard procedures. Histomorphometric parameters were calculated on the basis of standard formulas, as described previously.
